Tesa/IPA Protocol
Also known as: Tesa-IPA, Tesamorelin-Ipamorelin Blend, TI Blend
Tesamorelin + Ipamorelin GH Secretagogue Blend
Overview
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
Key benefits
- Synergistic GH release from dual pathways
- More physiological pulsatile GH secretion
- Tesamorelin's proven lipodystrophy benefits
- Ipamorelin's clean side effect profile
- Does not significantly affect cortisol or prolactin
- Single injection convenience
- May improve body composition, sleep, and recovery
Mechanism of action
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Molecular data
- Type
- Dual GH secretagogue combination
Sequence
Tesamorelin (GHRH analog) + Ipamorelin (GHRP)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Body Composition
Recovery & Wellness
Metabolic Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 200-400mcg total | Once daily (evening) | — |
| — | 300-500mcg total | Once daily (evening) | — |
| — | 200-300mcg per dose | Morning and evening | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Joint stiffness
- Increased hunger (Ipamorelin effect)
Rare side effects
- Headache
- Carpal tunnel-like symptoms
- Changes in blood glucose
- Fatigue
Contraindications
- Active malignancy (GH may promote tumor growth)
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders
- Hypersensitivity to components
Monitoring
- IGF-1 levels periodically
- Fasting glucose
- Body composition changes
- Sleep quality
- General well-being
References
Primary literature and clinical-trial data informing this entry.